Diffusion and perfusion imaging biomarkers of H3 K27M mutation status in diffuse midline gliomas.
Diffuse midline glioma
H3K27M
MRI
Journal
Neuroradiology
ISSN: 1432-1920
Titre abrégé: Neuroradiology
Pays: Germany
ID NLM: 1302751
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
20
06
2021
accepted:
08
11
2021
pubmed:
28
1
2022
medline:
14
7
2022
entrez:
27
1
2022
Statut:
ppublish
Résumé
H3K27M-mutant diffuse midline gliomas (M-DMGs) exhibit a clinically aggressive course. We studied diffusion-weighted imaging (DWI) and perfusion (PWI) MRI features of DMG with the hypothesis that DWI-PWI metrics can serve as biomarkers for the prediction of the H3K27M mutation status in DMGs. A retrospective review of the institutional database (imaging and histopathology) of patients with DMG (July 2016 to July 2020) was performed. Tumoral apparent diffusion coefficient (ADC) and peritumoral ADC (PT ADC) values and their normalized values (nADC and nPT ADC) were computed. Perfusion data were analyzed with manual arterial input function (AIF) and leakage correction (LC) Boxerman-Weiskoff models. Normalized maximum relative CBV (rCBV) was evaluated. Intergroup analysis of the imaging variables was done between M-DMGs and wild-type (WT-DMGs) groups. Ninety-four cases (M-DMGs-n = 48 (51%) and WT-DMGs-n = 46(49%)) were included. Significantly lower PT ADC (mutant-1.1 ± 0.33, WT-1.23 ± 0.34; P = 0.033) and nPT ADC (mutant-1.64 ± 0.48, WT-1.83 ± 0.54; P = 0.040) were noted in the M-DMGs. The rCBV (mutant-25.17 ± 27.76, WT-13.73 ± 14.83; P = 0.018) and nrCBV (mutant-3.44 ± 2.16, WT-2.39 ± 1.25; P = 0.049) were significantly higher in the M-DMGs group. Among thalamic DMGs, the min ADC, PT ADC, and nADC and nPT ADC were lower in M-DMGs while nrCBV (corrected and uncorrected) was significantly higher. Receiver operator characteristic curve analysis demonstrated that PT ADC (cut-off-1.245), nPT ADC (cut-off-1.853), and nrCBV (cut-off-1.83) were significant independent predictors of H3K27M mutational status in DMGs. DWI and PWI features hold value in preoperative prediction of H3K27M-mutation status in DMGs.
Identifiants
pubmed: 35083503
doi: 10.1007/s00234-021-02857-x
pii: 10.1007/s00234-021-02857-x
doi:
Substances chimiques
Biomarkers
0
Histones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1519-1528Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Alelú-Paz R, Ashour N, González-Corpas A, Ropero S (2012) DNA methylation, histone modifications, and signal transduction pathways: a close relationship in malignant gliomas pathophysiology. J Signal Transduct 2012:1–8
doi: 10.1155/2012/956958
Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 124(3):439–47
doi: 10.1007/s00401-012-0998-0
Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–31. https://doi.org/10.1038/nature10833
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820
doi: 10.1007/s00401-016-1545-1
Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB et al (2018) cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 135(4):639–42. https://doi.org/10.1007/s00401-018-1826-y
doi: 10.1007/s00401-018-1826-y
pubmed: 29497819
Daoud EV, Rajaram V, Cai C, Oberle RJ, Martin GR, Raisanen JM et al (2018) Adult brainstem gliomas with H3K27M mutation: radiology, pathology, and prognosis. J Neuropathol Exp Neurol 77(4):302–311
doi: 10.1093/jnen/nly006
Johnson DR, Guerin JB, Giannini C, Morris JM, Eckel LJ, Kaufmann TJ (2017) 2016 updates to the WHO brain tumor classification system: what the radiologist needs to know. Radiographics 37(7):2164–2180
doi: 10.1148/rg.2017170037
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, et al. The 2016 WHO classification of tumors of the central nervous system. International Agency for Research on Cancer (IARC), Lyon. 2016.
Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJJ et al (2016) Diffuse midline gliomas with histone H3–K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol 26(5):569–580
doi: 10.1111/bpa.12336
Lu QR, Qian L, Zhou X (2019) Developmental origins and oncogenic pathways in malignant brain tumors. Wiley Interdiscip Rev Dev Biol 8(4):1–23
doi: 10.1002/wdev.342
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251
doi: 10.1093/neuonc/noab106
Gojo J, Pavelka Z, Zapletalova D, Schmook MT, Mayr L, Madlener S et al (2020) Personalized treatment of H3K27M-mutant pediatric diffuse gliomas provides improved therapeutic opportunities. Front Oncol 9(January):1–14
Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M et al (2018) Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol 20(1):123–131
doi: 10.1093/neuonc/nox149
Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C (2014) Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol 128(4):573–581
doi: 10.1007/s00401-014-1319-6
Chen H, Hu W, He H, Yang Y, Wen G, Lv X (2019) Noninvasive assessment of H3 K27M mutational status in diffuse midline gliomas by using apparent diffusion coefficient measurements. Eur J Radiol 114:152–159
doi: 10.1016/j.ejrad.2019.03.006
Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM et al (2019) Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol. 143(1):87–93. https://doi.org/10.1007/s11060-019-03134-x
doi: 10.1007/s11060-019-03134-x
pubmed: 30864101
pmcid: 6482123
Aboian MS, Solomon DA, Felton E, Mabray MC, Villanueva-Meyer JE, Mueller S et al (2017) Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation. Am J Neuroradiol 38(4):795–800
doi: 10.3174/ajnr.A5076
Thust SC, Hassanein S, Bisdas S, Rees JH, Hyare H, Maynard JA et al (2018) Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis. Eur Radiol 28:3779–3788
doi: 10.1007/s00330-018-5351-0
Lee S, Choi SH, Ryoo I, Yoon TJ, Kim TM, Lee SH et al (2015) Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neurooncol 121(1):141–150
doi: 10.1007/s11060-014-1614-z
Patterson DM, Padhani AR, Collins DJ (2008) Technology insight: water diffusion MRI - a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol. 5:220–233
doi: 10.1038/ncponc1073
Cui Y, Ma L, Chen X, Zhang Z, Jiang H, Lin S (2014) Lower apparent diffusion coefficients indicate distinct prognosis in low-grade and high-grade glioma. J Neurooncol 119:377–385
doi: 10.1007/s11060-014-1490-6
Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML et al (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247(2):490–498
doi: 10.1148/radiol.2472070898
Rossi A, Gandolfo C, Morana G, Severino M, Garrè ML, Cama A (2010) New MR sequences (diffusion, perfusion, spectroscopy) in brain tumours. Pediatr Radiol 40(6):999–1009
doi: 10.1007/s00247-010-1613-y
Xing Z, Yang X, She D, Lin Y, Zhang Y, Cao D (2017) Noninvasive assessment of IDH mutational status in World Health Organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging. Am J Neuroradiol 38(6):1138–1144
doi: 10.3174/ajnr.A5171
Yamashita K, Hiwatashi A, Togao O, Kikuchi K, Hatae R, Yoshimoto K et al (2016) MR imaging-based analysis of glioblastoma multiforme: estimation of IDH1 mutation status. Am J Neuroradiol 37(1):58–65
doi: 10.3174/ajnr.A4491
Darbar A, Waqas M, Enam SF, Mahmood SD (2018) Use of preoperative apparent diffusion coefficients to predict brain tumor grade. Cureus. 10(3):e2284
pubmed: 29740523
pmcid: 5938001
Murakami R, Hirai T, Sugahara T, Fukuoka H, Toya R, Nishimura S et al (2009) Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method. Radiology 251(3):838–845
doi: 10.1148/radiol.2513080899
Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. Am J Neuroradiol 27(4):859–867
pubmed: 16611779
pmcid: 8134002
Saini J, Gupta RK, Kumar M, Singh A, Saha I, Santosh V et al (2019) Comparative evaluation of cerebral gliomas using rCBV measurements during sequential acquisition of T1-perfusion and T2-perfusion MRI. PLoS ONE 14(4):1–14
doi: 10.1371/journal.pone.0215400
Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM et al (2009) Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusio. Am J Neuroradiol 30(3):552–558
doi: 10.3174/ajnr.A1377
Wetzel SG, Cha S, Johnson G, Lee P, Law M, Kasow DL et al (2002) Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 224(3):797–803
doi: 10.1148/radiol.2243011014
Danchaivijitr N, Waldman AD, Tozer DJ, Benton CE, Caseiras GB, Tofts PS et al (2008) Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology 247(1):170–178
doi: 10.1148/radiol.2471062089
Mazur MD, Couldwell WT (2011) Investigating a candidate cell of origin for diffuse intrinsic pontine glioma. World Neurosurg. 76:368–373
doi: 10.1016/j.wneu.2011.08.027
Duchatel RJ, Jackson ER, Alvaro F, Nixon B, Hondermarck H, Dun MD (2019) Signal transduction in diffuse intrinsic pontine glioma. Proteomics. 19:e1800479
doi: 10.1002/pmic.201800479
Piccardo A, Tortora D, Mascelli S, Severino M, Piatelli G, Consales A et al (2019) Advanced MR imaging and 18F-DOPA PET characteristics of H3K27M-mutant and wild-type pediatric diffuse midline gliomas. Eur J Nucl Med Mol Imaging 46(8):1685–1694
doi: 10.1007/s00259-019-04333-4
Yao R, Cheng A, Liu M, Zhang Z, Jin B, Yu H (2021) The diagnostic value of apparent diffusion coefficient and proton magnetic resonance spectroscopy in the grading of pediatric gliomas. J Comput Assist Tomogr 45(2):269–276
doi: 10.1097/RCT.0000000000001130
Lee J, Choi SH, Kim JH, Sohn CH, Lee S, Jeong J (2014) Glioma grading using apparent diffusion coefficient map: application of histogram analysis based on automatic segmentation. NMR Biomed 27(9):1046–1052
doi: 10.1002/nbm.3153
Chawla S, Kim S, Wang S, Poptani H (2009) Diffusion-weighted imaging in head and neck cancers. Futur Oncol 5(7):959–975
doi: 10.2217/fon.09.77